<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Optimal management of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) is not confined to immediate diagnosis, early decision making and timely initiation of major treatment strategies (immunosuppression or SCT) but also involves supportive treatment as a crucial part of patient care </plain></SENT>
<SENT sid="1" pm="."><plain>Patients are threatened by complications of cytopenia </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we summarize current recommendations for prevention and early treatment of fungal, <z:mp ids='MP_0001794'>bacterial</z:mp> and <z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, transfusion strategy and iron chelation and assess the evidence basis </plain></SENT>
<SENT sid="3" pm="."><plain>In fact, many recommendations for patients with AA are not based on randomized studies in AA itself, but they are deduced from other conditions with similar severity of cytopenia </plain></SENT>
<SENT sid="4" pm="."><plain>Prevention and treatment of complications like <z:mp ids='MP_0001914'>hemorrhage</z:mp>, <z:mp ids='MP_0001794'>bacterial</z:mp> and <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e> and of secondary events like <z:e sem="disease" ids="C0948201" disease_type="Disease or Syndrome" abbrv="">alloimmunization</z:e> to blood products and <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> have a significant impact on the prognosis of AA patients and need to be carefully observed in daily practice </plain></SENT>
<SENT sid="5" pm="."><plain>More controlled studies on supportive care should be performed in this <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare disease</z:e> </plain></SENT>
</text></document>